title: Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.
abstract: OBJECTIVE
  Weight gain is an undesirable side effect of second-generation antipsychotics (SGAs). We performed this study to examine the influence of SGAs on resting energy expenditure (REE) and the relationship of REE to weight gain in adolescent patients.
  
  
  METHODS
  Antipsychotic-naïve or quasi-naïve (<72 h of exposure to antipsychotics) adolescent patients taking olanzapine, quetiapine, or risperidone in monotherapy were followed up for one year. We performed a prospective study (baseline, 1, 3, 6, and 12 months after treatment) based on anthropometric measurements, bioelectrical impedance analysis, and indirect calorimetry (Deltatrac™ II MBM-200) to measure REE. We also analyzed metabolic and hormonal data and adiponectin concentrations.
  
  
  RESULTS
  Forty-six out of the 54 patients that started treatment attended at least 2 visits, and 16 completed 1 year of follow-up. Patients gained 10.8 ± 6.2 kg (60% in the form of fat mass) and increased their waist circumference by 11.1 ± 5.0 cm after 1 year of treatment. The REE/kg body mass ratio decreased (p = 0.027), and the REE/percentage fat-free mass (FFM) ratio increased (p = 0.007) following the fall in the percentage of FFM during treatment. Weight increase was significantly correlated with the REE/percentage FFM ratio at all the visits (1-3-6-12 months) (r = 0.69, p = 0.004 at 12 months).
  
  
  CONCLUSIONS
  SGAs seem to induce a hypometabolic state (reflected as decreased REE/kg body mass and increased REE/percentage FFM). This could explain, at least in part, the changes in weight and body composition observed in these patients.
authors.affiliation: Unidad de Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, Spain. mcuerda.hgugm@salud.madrid.org
authors.forename: Cristina
authors.initials: C
authors.lastname: Cuerda
authors.forename: Jessica
authors.initials: J
authors.lastname: Merchan-Naranjo
authors.forename: Cristina
authors.initials: C
authors.lastname: Velasco
authors.forename: Alberto
authors.initials: A
authors.lastname: Gutierrez
authors.forename: Marta
authors.initials: M
authors.lastname: Leiva
authors.forename: Maria J
authors.initials: MJ
authors.lastname: de Castro
authors.forename: Mara
authors.initials: M
authors.lastname: Parellada
authors.forename: Marisa
authors.initials: M
authors.lastname: Giráldez
authors.forename: Irene
authors.initials: I
authors.lastname: Bretón
authors.forename: Miguel
authors.initials: M
authors.lastname: Camblor
authors.forename: Pilar
authors.initials: P
authors.lastname: García-Peris
authors.forename: Elena
authors.initials: E
authors.lastname: Dulín
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Sanz
authors.forename: Manuel
authors.initials: M
authors.lastname: Desco
authors.forename: Celso
authors.initials: C
authors.lastname: Arango
mesh_terms: D052242:Adiponectin / Q000097:blood; D000293:Adolescent; D041923:Adolescent Development / Q000187:drug effects*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001481:Basal Metabolism / Q000187:drug effects*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001823:Body Composition / Q000187:drug effects; D002648:Child; D015331:Cohort Studies; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D000077152:Olanzapine; D011446:Prospective Studies; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D055105:Waist Circumference / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects*
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D014150:Antipsychotic Agents; D015415:Biomarkers; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine